Letter to the Editor: Survey on DOACs in Cancer-Related Venous Thromboembolism
This letter is a follow-up to a report published previously in The ASCO Post.
Recent trials report comparable or improved efficacy of direct-acting oral coagulants (DOACs) over low–molecular-weight heparins (LMWH) in the treatment of cancer-related VTE (cVTE) at the expense of increased bleeding in certain cancers. Although these advances may lead to expanded use of DOACs in cVTE, we predict a significant variability in individual provider awareness, practice patterns, and implementation of consensus recommendations regarding the use of DOACs in cVTE. We anticipate that factors such as practice type, size, and location; provider and patient comfort; and external factors including medication costs and anticipated U.S. Food and Drug Administration approvals of DOACs in cVTE management will play significant roles in the uptake of emerging practice guidelines.
To explore these factors, we have developed a survey to examine the patterns of utilization and perspectives of providers regarding the use of DOACs vs other anticoagulants in cVTE. The results of this study will inform hematologists and oncologists regarding best practices for and barriers to the use of DOACs in cVTE.
The survey takes approximately 3–5 minutes to complete and can be taken on a mobile device. Your participation is highly valued to ensure the results are representative of actual practice patterns. The survey can be found at: https://yalesurvey.ca1.qualtrics.com/jfe/form/SV_3l0HxrreWZhVtBz.
Thank you very much,
Alexander B. Pine, MD, PhD
Alfred I. Lee, MD, PhD
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
